JAK inhibitor

New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...

This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.

New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from msn.com.

This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.

This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Upadacitinib. Open the original article for the...

This study provides real‑world data on upadacitinib’s ability to produce clinical and endoscopic remission in people with Crohn’s disease, information that can help patients and clinicians weigh treatment options.

Based on the title and source metadata, this appears to be a clinical study related to Irritable bowel syndrome, Upadacitinib, and JAK inhibitor. The original article is from msn.com.

This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...